{'fraction_non_alphanumeric': 0.026888604353393086, 'fraction_numerical': 0.016645326504481434, 'mean_word_length': 4.792592592592593, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Masitinib and Its Role in Inhibiting SARS-CoV-2 Infection

A drug used successfully in veterinary medicine to treat mast cell tumors in dogs may be effective against COVID-19 and some other viral diseases in humans, according to laboratory experiments and preclinical studies published in Science 2021 [1]. Coronaviruses also require such enzymes. After entering the cells, their genome is first converted into 2 polyproteins, which must be broken down into smaller units. This task is performed by 2 proteases. This is once the main protease 3CL (also called Mpro or nsp5). The 2nd enzyme is the "papain-like" protease, abbreviated PLpro. Drugs that block one of these enzymes could prevent the viruses from replicating in the cells and thus stop the progression of the infection.